Abstract
The development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs.
Keywords: Cancer, lymphoma, therapy, antibodies, phosphoantigens
Current Drug Targets
Title: Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies
Volume: 11 Issue: 7
Author(s): Aude-Helene Capietto, Samarh Keirallah, Emilie Gross, Nicolas Dauguet, Emilie Laprevotte, Christine Jean, Julie Gertner-Dardenne, Christine Bezombes, Anne Quillet-Mary, Mary Poupot, Loic Ysebaert, Guy Laurent and Jean-Jacques Fournie
Affiliation:
Keywords: Cancer, lymphoma, therapy, antibodies, phosphoantigens
Abstract: The development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs.
Export Options
About this article
Cite this article as:
Capietto Aude-Helene, Keirallah Samarh, Gross Emilie, Dauguet Nicolas, Laprevotte Emilie, Jean Christine, Gertner-Dardenne Julie, Bezombes Christine, Quillet-Mary Anne, Poupot Mary, Ysebaert Loic, Laurent Guy and Fournie Jean-Jacques, Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies, Current Drug Targets 2010; 11 (7) . https://dx.doi.org/10.2174/138945010791320845
DOI https://dx.doi.org/10.2174/138945010791320845 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Purine Nucleoside Analogues for the Treatment of Hematological Malignancies: Pharmacology and Clinical Applications
Current Cancer Drug Targets Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry 177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma
Current Radiopharmaceuticals Challenges and Advances in Infection Control of Hematopoietic Stem Cell Transplant Recipients
Infectious Disorders - Drug Targets Failure of Immune Homeostasis - The Consequences of Under and Over Reactivity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Synthetic Lipoproteins as Carriers for Drug Delivery
Current Medicinal Chemistry Metastatic Cancer Stem Cells: New Molecular Targets for Cancer Therapy
Current Pharmaceutical Biotechnology Poly(ADP-Ribose) Polymerases in Aging – Friend or Foe?
Current Protein & Peptide Science Antiangiogenesis in Myelodysplastic Syndrome
Current Cancer Drug Targets Apoptosis Induction by Erucylphosphohomocholine via the 18 kDa Mitochondrial Translocator Protein: Implications for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Anti-MDR Effects of Quercetin and its Nanoemulsion in Multidrug-Resistant Human Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Synthesis of 2-(Bis (2-Chloroethyl)Amino)-N-(5-Substitutedphenyl)- 1,3,4- Thiadiazol-2-Yl)Acetohydrazide And Evaluation of Anticancer Activity
Current Bioactive Compounds Radionuclide Imaging in Drug Development
Current Pharmaceutical Design Autoimmune Neuromuscular Disorders
Current Neuropharmacology EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer
Recent Patents on Anti-Cancer Drug Discovery The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets Pharmacogenetics of Colon Cancer and Potential Implications for 5- Fluorouracil-Based Chemotherapy
Current Pharmacogenomics Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Naturally Occurring Hydroxytyrosol: Synthesis and Anticancer Potential
Current Medicinal Chemistry Mechanism of Action of Flavonoids in Prevention of Inflammation- Associated Skin Cancer
Current Medicinal Chemistry